Low Level Laser Light Therapy as an Aid to Liposuction
Erchonia Medical, Inc., Erchonia EML Laser Liposuction Clinical Study V Protocol
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria: There were separate inclusion criteria for both the liposuction and the clinical study components of the study.
INCLUSION CRITERIA FOR THE LIPOSUCTION PROCEDURE
Prior to partaking in the clinical study qualification evaluation, an individual must have already:
- qualified as a patient for liposuction according to the American Society of Liposuction Surgery (ASLSS) and the American Academy of Cosmetic Surgery (AACS) 2000 Liposuction Guidelines.
- been deemed suitable for undergoing anesthesia according to the American Society of Anesthesiologists: Preanesthesia Evaluation guidelines: Basic Standards For Preanesthesia Care (Approved by House of Delegates on October 14, 1987).
- Signed the physician's standard informed consent form for the liposuction procedure itself.
INCLUSION CRITERIA FOR THE CLINICAL STUDY
- Signed clinical study informed consent form.
- Liposuction procedure intended for the removal of localized deposits of adipose tissue for the purpose of body contouring.
- Body Mass Index (BMI) in kg/m2 of less than 30 (non-obese).
- Localized areas of protruding fat deemed suitable for body contouring liposuction according to the investigator's professional training and experience as for a patient presenting with the same profile and not being considered for participation in the study.
- Areas of treatment to include only one or more of the right and/or left sides of the stomach, thigh, and hips.
- 'Overall firm elastic skin,' as defined by passing of the "snap test" for each intended treatment area.
- American Society of Anesthesiology (ASA) Physical Status Classification System rating of P1: a normal healthy patient or P2: a patient with mild systemic disease, as determined by standard physical examination.
- Suitable for general intubation anesthesia.
- 18 to 55 years, inclusive.
EXCLUSION CRITERIA
- Liposuction procedure intended for the treatment of diseases, such as lipomas, gynecomastia, pseudogynecomastia, lipodystrophy and axillary hyperhydrosis; for the reconstruction of the skin and subtissues in flap elevations, subcutaneous debulking, flap movement or other conditions; to obtain fat for fat transfer (for such purposes as augmentation, correction of scar defects, etc.), and for weight loss.
- ASA Physical Status Classification System rating of P3 to P5.
- Use of narcotics, opiates, steroids and/or NSAIDs within one week prior to surgery.
- Any prior surgery to any of the area(s) to receive liposuction.
- Active infection or wound in any part of the body, including the intended areas of treatment.
- Arthritis or other disorders or injury that directly affect the areas to be treated, including any implants such as pins.
- History of thrombotic events.
- History of neurologic disorder e.g. sensory loss or dysthesia in any of the area(s) to be treated.
- Diabetes.
- Immuno-compromised state, e.g., HIV infection, radiation, chemo or other cancer therapy within the last 6 months.
- Potential bleeding tendencies due to the use of aspirin, non-steroidal anti-inflammatory drugs, estrogen, Vitamin E, herbal supplements such as ginseng, ginger.
- Potential hypercoagulability, e.g., tamoxifen therapy, cancer, recent significant trauma, dehydration.
- Developmental disabilities that affect the ability to read and/or understand the consent form and any other information that may be required from the subject.
- Significant psychological disorder(s) for which treatment has become necessary, including anxiety and depression; psychiatric hospitalization.
- Pregnancy or lactation.
- Involvement in litigation and/or receiving disability benefits related to any kind of disability, injury, or other problem in any one or more of the area(s) to receive liposuction.
- Participation in research during the prior 90 days.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
PLACEBO_COMPARATOR: placebo laser
inactive light on the laser device.
|
|
|
ACTIVE_COMPARATOR: Erchonia (R) LipoLASER PL
The Erchonia(R) LipoLASER PL is a low level laser light therapy medical device that was applied during the liposuction procedure, by emitting 1 mw of red (635nm wavelength) light via a Class II electric laser diode energy source (CDRH classification).
The fluence is considered to be at 10.8 joules per area treated.
|
The Erchonia(R) EML Laser is a low level laser light therapy medical device that was applied during the liposuction procedure, by emitting 1 mw of red (635nm wavelength) light via a Class II electric laser diode energy source (CDRH classification).
The fluence is considered to be at 10.8 joules per area treated.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Subject self-reported Degree of Pain rating on the standardized 0-100 Visual Analogue Scale (VAS) at 24 hours post-surgery.
Time Frame: 24 hours
|
24 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Ease of the process of fat extraction during the liposuction procedure
Time Frame: immediately post surgery
|
immediately post surgery
|
|
Emulsification (consistency) of extracted fat
Time Frame: immediately post surgery
|
immediately post surgery
|
|
Amount of time spent by volume of fat removed
Time Frame: Immediately post surgery
|
Immediately post surgery
|
|
Degree of swelling at the surgical site
Time Frame: 7 days post surgery
|
7 days post surgery
|
|
Subject self-reported degree of post-surgical pain
Time Frame: 7, 14 and 28 days post surgery
|
7, 14 and 28 days post surgery
|
|
Use of recovery pain medication
Time Frame: Through the 1st 7 post-surgical days
|
Through the 1st 7 post-surgical days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Kimberly Butterwick, MD
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- ELIPO-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.